Editor’s note: The approvals are listed from most to least recent.
- Biogen’s Aduhelm — The first treatment approved by the FDA to slow cognitive decline from Alzheimer’s disease and the first new Alzheimer’s drug approved in nearly two decades.
- Novo Nordisk’s Wegovy — An injectable drug designed for chronic weight management in adults with obesity.
- ProMetic Biotherapeutics’ Ryplazim — A drug designed to treat patients with plasminogen deficiency type 1, also called hypoplasminogenemia, a disorder that can impair normal tissue and organ function and that may lead to blindness.
- Amgen’s Lumakras — The first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.
- Johnson & Johnson’s Rybrevant — The first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations.
- AstraZeneca’s Farxiga — Oral tablets intended to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.
